Contact Information: Contact: Cellceutix Corp. Leo Ehrlich (978) 633-3623
Cellceutix Abstract Accepted by AACR
Important New Data on Kevetrin (TM) to Be Presented at April Meeting
| Source: Cellceutix Corporation
BEVERLY, MA--(Marketwire - March 15, 2010) - Cellceutix Corporation (OTCBB : CTIX ), a
bio-pharmaceutical company that develops small molecules to treat cancer
and inflammatory disease, today announced that the American Association for
Cancer Research (AACR) has accepted an abstract of data on Kevetrin for
presentation at its 101st Annual Meeting from April 17th to 22nd in
Washington, DC. This abstract titled "Novel small molecule has potent
anti-tumor activity in drug resistant tumor xenograft models" contains data
on Kevetrin that have not previously been made public. The abstract will
be presented at a session entitled "Late-Breaking Research: Experimental
and Molecular Therapeutics 2," on April 20.
"This is a significant event for Cellceutix," said its Chief Scientific
Officer, Dr. Krishna Menon. "The AACR is the premier cancer research
organization and its annual meeting attracts scientists and pharma
executives throughout the world. We are pleased to be able to present our
data at the upcoming meeting."
In animal studies, Kevetrin was found to significantly delay tumor growth
in multi-drug resistant lung, breast and colon cancer cell lines. More
information about these studies is available on the Cellceutix web site at
www.cellceutix.com.
About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug
developer. Cellceutix owns the rights to eight drug compounds, including
Kevetrin, which it is developing as a treatment for certain cancers, and
KM-391, which it is developing for the treatment of autism. More
information is available on the Cellceutix web site at www.cellceutix.com.
This Press Release contains forward-looking statements that are based on
our current expectations, beliefs and assumptions about the industry and
markets in which Cellceutix Corporation operates. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors that may cause Cellceutix's actual results to be materially
different from any future results expressed or implied by these
statements. Actual results may differ materially from what is expressed in
these statements, and no assurance can be given that Cellceutix can
successfully implement its core business strategy and improve future
earnings.
The factors that may cause Cellceutix's actual results to differ from its
forward-looking statements include: Cellceutix's current critical need for
additional cash to sustain existing operations and meet ongoing existing
obligations and capital requirements; Cellceutix's ability to implement its
new product development and commercialization, enter into clinical trials,
expand the intellectual property portfolio, and receive regulatory
approvals in a timely and cost-effective manner. All forward-looking
statements are also expressly qualified in their entirety by the cautionary
statements included in Cellceutix's SEC filings, including its quarterly
reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The
Company's positive results in animal studies do not necessarily guarantee
success in humans, though they may form the basis for beginning Phase 1
trials.